Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$91.4M
33M shares
52-week range
$1.91 – $4.53
41% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
www.fortressbiotech.comNo one on the platform currently holds FBIO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 99,590 | $277.9K |
| Execution date | Ratio |
|---|---|
| 2023-10-10 | 1-for-15reverse |
No one on the platform has traded FBIO yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $80M | +8.9% | $2.40 | $2.40–$2.40 | 1.2× | 1 |
| 2027 | $123M | +54.0% | $-0.50 | $-0.50–$-0.50 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.20 | $-0.08 | +60.0% |
| 2026-05-14 | $-0.22 | $2.82 | +1381.8% |
| 2026-03-31 | $0.42 | $-0.21 | -150.0% |
| 2025-11-14 | $-0.43 | $0.11 | +125.6% |
| 2025-08-14 | $-0.31 | $-0.46 | -48.4% |
| 2025-05-21 | $-0.44 | $-1.03 | -134.1% |
| 2025-03-27 | $-0.79 | $-0.53 | +32.9% |
| 2024-11-14 | $-0.27 | $-0.76 | -181.5% |
| $226M |
| — |
| NTRBNutriband Inc. | $3.19 | +3.74% | $39M | — |
| PMVPPMV Pharmaceuticals, Inc. | $1.22 | -3.57% | $65M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$FBIO so back to loss making. The only positive would be the cash at hand thanks to last months transaction... eh, just to pay the accrued dividends + interest, EVENTUALLY... maybe, maybe not. For the rest, I was right, dying business till the next big discovery and sale... that will probably cost money in R&D in the meanwhile. No thanks. GL
View on StockTwits ↗Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $FBIO $SNDX $SNDK Long it
View on StockTwits ↗$FBIOP $FBIO Quick refresher on the milestone payments due to Cyprium for ZYCUBO sales: Given 0.3m royalty payments from ZYCUBO, we can assume that 10m in revenues were realized in the first 6 months of launching. The first milestone payment of 2.5m triggers at 75m in yearly sales (75m in yearly sales produces an additional 2.25m in royalties) The 2nd milestone payment of 12.5m triggers at 125m in yearly sales (royalty payment bumps from 3% to 12% if sales exceed 100m, 15m in royalties) The 3rd milestone payment of 17.5m triggers at 175m in yearly sales (175m in yearly sales produces an additional 21m in royalties) The 4th milestone payment of 20m triggers at 200m in yearly sales (200m in yearly sales produces an additional 24m in royalties) The 5th milestone payment of 37.5m triggers at 300m in yearly sales (300m in yearly sales produces an additional 36m in royalties) The 6th milestone payment of 37.5m triggers at 400m in yearly sales (+ 48m in royalties)
View on StockTwits ↗$FBIO This PR outside of nothing about dividends resuming is great though. Catalysts on the horizon. Those data readouts are important that they mentioned
View on StockTwits ↗$FBIO 300k from royalties in q2 for both unloxcyt and zycubo. I know those are newly launched, but those numbers definitely need to be higher sooner rather than later
View on StockTwits ↗$FBIO earnings released no mentioned of reinstatement with $FBIOP seems like they just are content to sit on cash and not help the preferred holders
View on StockTwits ↗$FBIO we fell way too far we need to catch up we should make a run towards 3.50-3.60 than float sideways for a few weeks before the real fun begins! Our climb towards 5.70. We are firing up the engines.
View on StockTwits ↗$FBIO so we expect actual Q2 earnings after close today. Is there going to be a call as well?
View on StockTwits ↗$FBIO you get excited here and then the stock snatches you back to reality. Look like we were running past $3. Nope.
View on StockTwits ↗$FBIO Just a heads-up: the Stocktwits “FBIO Q2 ’26 Earnings Results” post appears to be mislabeled. The linked 8-K/PDF is actually Fortress Biotech’s Q1 2026 results from May 14, not the new Q2 release. The $108.4M net income / $2.82 diluted EPS figures are Q1 numbers driven by the $205M PRV sale. DERM/Journey Medical did report Q2, but I still don’t see the actual FBIO consolidated Q2 results/10-Q posted yet. Check the document date/title before relying on the automated recap.
View on StockTwits ↗$FBIO never can have a day. After hours plummet. Shocker here.
View on StockTwits ↗$FBIO looks positive to me we should be on our run up.
View on StockTwits ↗$FBIO Q2 '26 Earnings Results & Recap Fortress Biotech reported Q1 2026 consolidated net income of $108.4 million, or $2.82 per diluted share, driven by a $205 million priority review voucher sale, compared to a prior year loss.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.